SUMMARY. The pituitary hormones prolactin and growth hormone are related single-chain polypeptides. Both hormones exist in the circulation in several molecular forms, and this heterogeneity may account for some of the complex and sometimes contradictory actions, in vivo and in vitro, of both hormones. It may also lead to problems with quantitation by immunoassays and discrepancies between the results given by assays using different antibodies. Modified forms of the hormones may have markedly different activity in bioassays from that of the parent hormone, but the clinical significance of this is unclear. In this review we summarize what is known about the molecular heterogeneity of the hormones and briefly discuss the implications for clinical biochemists.
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Over the last 10 years there have been major developments in understanding the relationship between the structure and function of the pituitary peptide hormones. The glycoprotein hormones follitropin (FSH) and lutropin (LH), for example, are now known to exist in the circulation in a number of different forms depending on the composition of their carbohydrate units."? Activity in immunoassays may be determined primarily by the peptide chain and thus be unrepresentative of the biological activity of the hormone, which is modified by the carbohydrate group.Y The importance of molecular heterogeneity in the physiology of human prolactin (hPRL) and human growth hormone (hGH) has only recently been appreciated. Major sources of molecular heterogeneity of both hormones are summarized in Tables 1 and 2. mE JipRL AND hGH GENE FAMILY The hGH and hPRL are believed to have evolved as a result of duplications of a common ancestral gene. Studies of other animal growth hormones have shown, however, that hGH differs consider- ably from any of the non-primate GHs in both amino-acid sequence and biological activity, with hGH the only GH with substantial lactogenic activity. Although hPRL is less different from most non-primate PRLs, rat PRL differs considerably in amino-acid sequence from other mammalian PRLs. 5 The hPRL gene appears to be present 'as a single copy and is located on chromosome 6. 6 The hGH gene cluster is found on chromosome 17,7 and probably consists of the normal human pituitary hGH gene (hGH-N), three human placental lactogen (hPL) genes, one of which may be non-functional, and the hGH-variant (hGH-V) gene. 8 • 9 All these genes have in common a five-exon structure and each encodes a protein product of 22-26 kD molecular weight.
The expression of the hGH-N gene is restricted to the somatotrophs of the anterior pituitary; expression of the hPL genes is restricted to the syncytiotrophoblast cells of the placenta. The hGH-V gene has recently been shown to be expressed in the placenta." The hPRL gene is expressed in the pituitary lactotrophs, the decidua of the placenta and in luteal phase endometrium.
MOLECULAR STRUCfURE OF hPRL AND hGH
hPRL is a single-chain polypeptide with an approximate molecular weight (MW) of 23 kD ( Fig. 1 ). Amino-acid sequencing of hPRL derived from a pool of normal pituitaries suggested a 198 amino-acid sequence. I I More recently, sequencing of hPRL cDNA from pituitary adenoma tissue has revealed an almost identical 199 amino-acid sequence. 12 hGH is also a singlechain protein, with the major circulating form having 191 residues and a MW of 22 kD 1J (Fig.   2 ). There is considerable (42%) homology between the coding sequences of the hPRL and hGH genes. The structures of both hormones are stabilized by intra-chain disulphide bonds.
The three-dimensional structure of a genetically-engineered variant of porcine GH was determined recently:" a large proportion of the molecule was found to consist of four IXhelices folded to form a compact globular structure. In view of the similarities in amino-acid sequence, it is likely that hGH and hPRL assume a similar shape. Elegant studies by Cunningham et al. 15 • 16 of the effects on binding characteristics of mutations introduced at various points have allowed the mapping of receptor and monoclonal antibody binding sites on the hGH molecule. The receptor binding-site consists of three sequences, COOH FIGURE 1. Monomeric hPRL. A polypeptide of 199 amino acids with three disulphide bridges. remote in the linear sequence, which are contiguous when the molecule is folded ( Fig. 3 ).
VARIANT FORMS DERIVED FROM DIFFERENT GENES
The hGH-N gene directs the synthesis of the 22 kD polypeptide, pituitary hGH, and a posttranscriptionally modified form, hGH 2okD , which is described below and constitutes approximately 10% of pituitary hGH.
The hGH-V gene codes for an hGH-like hormone which differs from pituitary hGH in 13 arnino-acids.v" It is likely that the recentlydescribed hGH-like peptide found in maternal serum in the third trimester" represents the product of the hGH-V gene expressed in the placenta. It has recently been reported that, as for the product of the hGH-N gene, alternative splicing of the hGH-V gene primary transcript can result in the production of two distinct proteins (designated hGH-V and hGH_V2). 18.19 There is no evidence for more than one hPRL gene and variant forms of hPRL appear to be post-translational modifications of the product of a single gene. hGH 20kD Translation ofmRNAs derived from the hGH-N gene results in synthesis of two distinct polypeptides, hGH m D and hGH 2okD • It is now clear that the smaller peptide is formed as a result of the use of an alternative splice-acceptor site within exon 3 of the hGH-N gene,18.20 resulting in an internal deletion of bases coding for 15 amino acids" (Fig. 4 ). The regulation of gene processing by the two routes is not understood. A third mRNA variant lacking the entire third exon has also been detected in pituitary tumour tissue," but the predicted 17·5 kD protein product has not yet been definitively identified. There is no evidence for the existence of analogous hPRL variant forms. 
POST-TRANSLATIONAL MODIFICATIONS Glycosylation
A glycosylated form of hPRL (G-hPRL) is consistently found in human pituitaries and sera." An oligosaccharide side-chain is attached at Asn., , resulting in a molecule of apparent MW 25 kD determined by sodium dodecyl sulphate (SDS) electrophoresis. Recent work shows that G-hPRL is a major circulating form in normal sera." We have found that G-hPRL constituted approximately 70% of total monomeric hPRL in a study of 42 normal subjects. The proportion of G-hPRL falls with increasing levels of serum hPRL, and some patients with extremely high hPRL levels may have no detectable G-hPRL in their serum." Very recent work suggests that there may be more than one form of G-hPRL. 26 G-hPRL is also found in amniotic fluid and is a secretory product of luteal phase endometrium" and also of placenta."
The Asn-Gln/Leu-Ser sequence at which Nlinked glycosylation occurs does not occur in pituitary hGH but is present in the placental variant. Work by Ray et al. 29 suggests that hGH-V is modified by N-linked glycosylation in a fibroblast cell-line, and there is some evidence that the placental product is glycosylated in man."
Charge variants Charge variants of both hormones, such as acetylated and deamidated forms, have been described in serum; it is not clear whether these represent artefacts or secreted forms."
Aggregates and oligomers Fractionation of serum by gel filtration consistently reveals three major species of hGH: MW approximately 20-22 kD (monomeric or little hGH), 40-50 kD (big hGH) and> 60 kD (big big hGH). 32 Similarly, three species of hPRL are found in serum with MW 23 kD (monomeric or little hPRL), 50-60 kD (big hPRL), and > lOOkD (big big hPRL). 33-3s 'Big big' forms of both hormones are mainly non-covalently bound aggregates.l":" and in the case of hPRL may be glycosylated." The complex formed by hGH and its serum binding protein (see below) probably accounts for most 'big big' hGH. 37 'Big' forms of both hormones are predominantly dimers,32.38 some disulphidelinked, which appear to be secretory products. High molecular weight forms of hGH normally represent approximately 15-50% of total im-Pro/actin and growth hormone 545 munoactive hGH in serum.V The proportion of 'little' hGH has been shown in one study to be higher in acromegalic patients." Less than 20% of serum hPRL is present in high MW forms in sera from both normal subjects and some patients with hyperprolactinaernia,":" although higher proportions of high MW forms of hPRL are found in some patients with pituitary tumours.":" Some women with hyperprolactinaemia and normal ovarian function have been shown to have very high levels of high molecular weight hPRL in their serum.4(}-42
Proteolytically eleaved forms and fragments When circulating hPRL and hGH are subjected to immunoelectrophoresis under reducing conditions several low MW forms are detected. It has been suggested that the intact monomeric form of each hormone may be subjected to sequential attack by specific proteases to generate biologically active fragments with different functions.i':" Modified forms of both hormones have been described in which the large loop is opened; subsequent reduction of the intrachain disulphide bonds generates low molecular weight fragments.
Cleaved forms ofhPRL appear to be present in tissues such as pituitary and ovary and have also been demonstrated in serum from pregnant women." It is not certain that low MW fragments are produced in vivo, but this idea has generated considerable interest in view of evidence that the 16kD fragment of rat PRL is biologically active despite reduced immunoactivity and may have important local effects. 43 
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Immunoactive hGH variants of MW 12-30 kD may contribute significantly to the total immunoactivity of hGH in normal sera in the basal state;" their contribution to hGH bioactivity is unknown. However, fragments of hGH generated in vitro have been shown to have enhanced activity in some bioassays" and may act through specific receptors. Their physiological functions are unknown.
SERUM BINDING PROTEINS
Until recently it was thought that both hormones existed free in the circulation. It has recently become clear however that a specific, high-affinity, low-capacity hGH binding protein (BP) exists in human plasma." Under physiological conditions, about 50% of hGH m D and 30% of hGH 20kD are bound. The rabbit GH BP has the same amino-acid sequence as the amino-terminal end of the GH receptor, suggesting that in this species the BP is the free extra-cellular domain of the receptor." This relationship between the serum binding protein and the hGH receptor has not been confirmed in man. As yet, no convincing evidence for a hPRL serum BP has been obtained.
The effect of the hGH BP on the measurement of hGH levels in blood is likely to be dependent on the relative affinities for hGH of the antiserum used in the assay and the BP. Preliminary data from Baumann et a/. 37 suggest that the affinity of antiserum for bound hGH is likely to exceed that of the BP, so hGH will preferentially bind to the antiserum. The complex of hGH with the major BP is in fact fully immunoactive, although a small proportion of hGH bound to a minor BP may be underestimated by RIA. This is unlikely to represent more than 10-15% of total plasma hGH.
CLINICAL SIGNIFICANCE OF MOLECULAR HETEROGENEITY
The full clinical significance of the variant forms of the hormones is unclear. Tables 3 and 4 summarize what is known about the physiological and analytical significance of variant forms of both hormones in serum.
The properties of modified forms of the hormones may help us to understand situations where there appear to be discrepancies between the results of immunoassay measurements of the ho~ones and the clinical picture. The preservation of normal ovarian function, with maintained fertility, in women with very high immunoassayable hPRL levels is one such example/":" Such women have been shown to have high serum levels of high MW hPRL oligomers which may be of reduced bioactivity." Current immunoassay methods do not allow the routine detection of such patients, who may not require treatment, although serial dilution of their sera may show non-parallelism with monomeric hPRL standard." Similarly, immunoactive but bioinactive hGH has been suggested as a cause of short stature. Subnormal ratios of hGH radioreceptor or bioassay activity to immunoactivity have been found in a smalI number of children, who respond weli to treatment with hGH. 48 -1O One such case of growth failure due to bioinactive hOH was shown to be caused by the presence in serum of large amounts ofhOH oligomers which showed decreased binding to the hGH receptor of human IM9 lymphocytes. 51 
ANALYTICAL SIGNIFICANCE OF MOLECULAR HETEROGENEITY
Immunoassays depend on the binding of one or more antibodies to binding sites on the target hormone; such sites may be distant from the binding sites for physiologicalIy-relevant ligands. Immunoassays may thus detect biologicalIy inactive hormone fragments or aggregates, or fail to detect bioactive fragments where the assay antibody binding site is absent or obscured.
Antibodies for use in immunoassays are usualIy raised against the unmodified monomeric form of the hormone, and may not detect modified but bioactive forms. Reference preparations for use in immunoassay also consist of purified monomeric hormone and so may not reflect the composition of the hormone in the serum being assayed.
In view of the marked fluctuations in the proportions of hOH and hPRL variants with different MWs and immunoactivities in serum, there is a strong case for continuing to report results of assays for these hormones in international units rather than mass units.
The molecular heterogeneity of the hormones raises the question of the significance of possible in vitro interconversions between forms, particularly mass variants. Variable conversion of high to low molecular weight forms of both hormones is known to occur with treatment with reducing agents, or multiple freeze-thaw cycles. Under usual assay conditions this does not appear to cause problems, but there is some evidence that heat treatment of serum, as may be used for HIV positive samples, can significantly alter apparent immunoactivity in at least one RIA. 52 Comparisons between different immunoassays Systematic comparisons between assays using Prolactin and growth hormone 547 different antisera are carried out as part of the validation of new methods but there are few published reports in the UK literature. In the case of hPRL, some antisera recognize high MW variants less welI than others":" and this may explain the non-paralIelism sometimes found on dilution of samples with very high hPRL concentrations. Immunoradiometric assays (IRMAs) using monoclonal antibodies, usualIy directed at two non-overlapping epitopes to form a 'sandwich', tend to give lower estimates of hPRL levels than do radioimmunoassays (RIAs) or bioassays'v" and may not recognize some forms of the hormone.
Comparisons of hOH results by different immunoassays provide evidence of considerable variation; up to three-fold differences in absolute results, both between RIA and IRMA and between different IRMAs have been reported.":" A least one commercial IRMA does not detect hOH 2okD at alI. 57 Such data re-emphasize the importance of establishing familiarity with one assay method and appropriate local reference and 'action' ranges. Similar problems have been experienced with IRMAs for gonadotropins. 58 
Comparison between immunoassay and bioassay results
The recent development of a relatively simple and convenient bioassay for lactogenic hormones has facilitated comparative studies of their biological and immunoactivity. The Nb2 celI assay" uses a celI line derived from a lymphoma which developed in an oestrogen-treated male rat. The celIs proliferate in response to both hOH and hPRL: the assay can be made specific by using monoclonal antibodies or antisera to block one hormone.
There are now several studies reporting altered hPRL bioactivity:immunoactivity (B:I) ratios in situations where hPRL molecular heterogeneity is known to be altered. Using the Nb2 cell bioassay, we,bO and others," have found bioactivity to be reduced compared with immunoactivity in some patients with prolactinomas. This may relate to the reduction in the proportion of serum hPRL which is glycosylated in sera from these patients, since glycosylation has significant effects on both the bioactivity and immunoactivity of the molecule.F:" In uraemic or myxoedematous patients we/ 5 • M like Rowe et al., 65 have been unable to demonstrate major differences between hPRL activity in the Nb2 assay and in immunoassays, although other workers have reported changes. 66 . 67 There are fewer studies of B:I ratios ofhOH in serum. The insensitivity of even the Nb2 assay for hGH makes measurement of unstimulated hGH levels or confirmation of reduced bioactivity difficult in children with short stature, and results are conflicting.v?" Using the Nb2 assay, we and others have found no change in B:I ratios in sera from acromegalic patients after stimulation of the pituitary.":" Discrepancies between studies of B:I ratios may relate to the immunoassay used for comparison with the bioassay, and definitive answers await the isolation of individual variants such as G-hPRL in sufficient amounts for their use as standards and to raise specific antibodies. Since changes in the molecular heterogeneity of the hormone, such as glycosylation, affect both immunological and biological activities, determination of B:l ratios may conceal important changes in the proportions of hormone variants. CONCLUSIONS I. hGH and hPRL do not circulate as single molecular species but as 'families' of related forms.
2. In a few patients, the molecular heterogeneity of the hormones may help to explain clinical paradoxes.
3. The development of new immunoassay methods, including those involving monoclonal antibodies, is leading to recognition of variability between immunoassays; the importance of establishing reference ranges is emphasized.
Despite the heterogeneity of hPRL and hGH,
immunoassay results generally correlate well with those of bioassays and will remain the standard method of measurement of these hormones in routine practice. In future assays for variants such as G-hPRL may provide additional information of clinical importance.
5.
In view of the heterogeneity of the hormones, there is a good case for using international rather than mass units to express immunoassay results.
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